TrialResults - center   -  Clinical trials results database in cardiology

GAMMA

You are here:  Home > Search and browse > Browse treatment 3

Clinical trials of Pradaxa (dabigatran)     pdf

Clinical trials of Pradaxa (dabigatran) and meta-analysis are available for the following clinical conditions:

atrial fibrillation

atrial fibrillation, antithrombotics, primary prevention of thromboembolic events    pdf

dabigatran vs warfarin standard dose :  phase 2 dabigatran, 0  -  RE-LY (110mg), 2009  -  PETRO (150mg), 2007  -  RE-LY (150mg), 2009  - 

atrial fibrillation, direct antithrombins, all type of patients    pdf

dabigatran 110mg vs warfarin standard dose :  RE-LY (110mg), 2009  -  PETRO (150mg), 2007  -  RE-LY (150mg), 2009  - 

atrial fibrillation, new anticoagulants, all type of patients    pdf

dabigatran vs warfarin standard dose :  phase 2 dabigatran, 0  -  RE-LY (110mg), 2009  -  PETRO (150mg), 2007  -  RE-LY (150mg), 2009  - 

atrial fibrillation, antithrombotics, secondary prevention of thromboembolic events    pdf

dabigatran 100mg vs warfarin :  RE-LY 110mg subgroup, 2010  -  RE-LY 150mg subgroup,  - 

DVT prophylaxis

DVT prophylaxis, antithrombotics, orthopedic surgery    pdf

dabigatran 150mg vs enoxaparin :  RE-NOVATE (150mg), 2007  -  RE-NOVATE (220mg), 2007  -  RE-NOVATE 2, 0  - 
dabigatran 150mg vs enoxaparin (europe regimen) :  RE-MODEL (150mg), 2007  -  RE-MODEL (220mg), 2007  -  BISTRO II (225mg bid), 2005  - 
dabigatran 150mg vs enoxaparin (US regimen) :  RE-MOBILIZE (150mg), 2008  -  RE-MOBILIZE (220mg), 2008  - 

DVT prophylaxis, antithrombotics, elective major knee surgery    pdf

dabigatran 150mg vs enoxaparin (europe regimen) :  RE-MODEL (150mg), 2007  -  RE-MODEL (220mg), 2007  - 
dabigatran 150mg vs enoxaparin (US regimen) :  RE-MOBILIZE (150mg), 2008  -  RE-MOBILIZE (220mg), 2008  - 

DVT prophylaxis, antithrombotics, elective hip replacement    pdf

dabigatran 150mg vs enoxaparin :  RE-NOVATE (150mg), 2007  -  RE-NOVATE (220mg), 2007  -  RE-NOVATE 2, 0  - 

DVT prophylaxis, anticoagulant, orthopedic surgery    pdf

dabigatran 150mg vs enoxaparin :  RE-NOVATE (150mg), 2007  -  RE-NOVATE (220mg), 2007  -  RE-NOVATE 2, 0  - 
dabigatran 150mg vs enoxaparin (europe regimen) :  RE-MODEL (150mg), 2007  -  RE-MODEL (220mg), 2007  -  BISTRO II (225mg bid), 2005  - 
dabigatran 150mg vs enoxaparin (US regimen) :  RE-MOBILIZE (150mg), 2008  -  RE-MOBILIZE (220mg), 2008  - 

DVT prophylaxis, direct antithrombins, all type of patients    pdf

dabigatran 150mg vs enoxaparin :  RE-NOVATE (150mg), 2007  -  RE-NOVATE (220mg), 2007  -  RE-NOVATE 2, 0  - 
dabigatran 150mg vs enoxaparin (europe regimen) :  RE-MODEL (150mg), 2007  -  RE-MODEL (220mg), 2007  -  BISTRO II (225mg bid), 2005  - 
dabigatran 150mg vs enoxaparin (US regimen) :  RE-MOBILIZE (150mg), 2008  -  RE-MOBILIZE (220mg), 2008  - 

DVT prophylaxis, new anticoagulants, all type of patients    pdf

dabigatran 150mg vs enoxaparin :  RE-NOVATE (150mg), 2007  -  RE-NOVATE (220mg), 2007  -  RE-NOVATE 2, 0  - 
dabigatran 150mg vs enoxaparin (europe regimen) :  RE-MODEL (150mg), 2007  -  RE-MODEL (220mg), 2007  -  BISTRO II (225mg bid), 2005  - 
dabigatran 150mg vs enoxaparin (US regimen) :  RE-MOBILIZE (150mg), 2008  -  RE-MOBILIZE (220mg), 2008  - 

DVT prophylaxis, new anticoagulants, elective major knee surgery    pdf

dabigatran 150mg vs enoxaparin (europe regimen) :  RE-MODEL (150mg), 2007  -  RE-MODEL (220mg), 2007  -  BISTRO II (225mg bid), 2005  - 
dabigatran 150mg vs enoxaparin (US regimen) :  RE-MOBILIZE (150mg), 2008  -  RE-MOBILIZE (220mg), 2008  - 

DVT prophylaxis, new anticoagulants, elective hip replacement    pdf

dabigatran 150mg vs enoxaparin :  RE-NOVATE (150mg), 2007  -  RE-NOVATE (220mg), 2007  -  RE-NOVATE 2, 0  - 
dabigatran 450mg vs enoxaparin (europe regimen) :  BISTRO II (225mg bid), 2005  - 

DVT prophylaxis, new anticoagulants, orthopaedic surgery    pdf

dabigatran 150mg vs enoxaparin :  RE-NOVATE (150mg), 2007  -  RE-NOVATE (220mg), 2007  -  RE-NOVATE 2, 0  - 
dabigatran 150mg vs enoxaparin (europe regimen) :  RE-MODEL (150mg), 2007  -  RE-MODEL (220mg), 2007  -  BISTRO II (225mg bid), 2005  - 
dabigatran 150mg vs enoxaparin (US regimen) :  RE-MOBILIZE (150mg), 2008  -  RE-MOBILIZE (220mg), 2008  - 

post acute coronary syndromes

post acute coronary syndromes , antithrombotics, all type of patients    pdf

dabigatran vs placebo :  REDEEM, 2009  - 

post myocardial infarction

post myocardial infarction, antithrombotics, all type of patients    pdf

dabigatran vs placebo :  REDEEM, 2009  - 

venous thrombosis

venous thrombosis, antithrombotics, all type of patients    pdf

dabigatran vs vitamin K antagonists :  RE-COVER, 2009  - 

venous thrombosis, antithrombotics, secondary prevention of VTE    pdf

dabigatran vs placebo :  RE-SONATE,  - 

venous thrombosis, direct antithrombins, all type of patients    pdf

dabigatran vs vitamin K antagonists :  RE-COVER, 2009  - 

Entry terms: dabigatran, N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine, dabigatran, dabigatran etexilate, BIBR 1048

Search Pradaxa clinical trials in Pubmed

Search Pradaxa clinical trials in ClinicalTrials.gov

Search Pradaxa clinical trials in Wikipedia

Search Pradaxa in drugs.com

browse_trt3b

This site complies to the HONcode standard for trustworthy health information: verify here.

Last uptaded on 2011/2 89 user(s) connected

TrialResults-center database by TrialResults-center is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License .

OpenSearch feed - Add TrialResults-center.org to your browser's search bar